Daily News: Reuters Health News Headlines - Belgium's MDxHealth signs U.S. deal for cancer test

	Yahoo! News | My Alerts | Edit Alert
Monday, Sep 02, 2013 11:25 PM PDT
Today's Reuters Health News Headlines - Yahoo! News: Belgium's MDxHealth signs U.S. deal for cancer test Amgen, Cytokinetics heart failure drug misses goal in study Novartis says EU approves Ilaris to treat childhood arthritis Facebook peer groups may be useful for HIV education Italian poultry worker tests positive for avian flu British cost watchdog recommends Thrombogenics eye drug Hospital to home focus may reduce readmissions: study Novartis heart failure drug effective across patient groups HEMP Party has high ambitions in Australian election Doctors get good and bad safety news on diabetes drugs Not your grandmother's gym class

Belgium's MDxHealth signs U.S. deal for cancer test  Monday, Sep 02, 2013 11:25 PM PDT BRUSSELS (Reuters) - Belgian biotech firm MDxHealth has signed a deal with U.S. healthcare network Stratose, which will give its prostate cancer testing product access to one of the largest networks in the United States. MDxHealth said on Tuesday that with the signature of the Stratose agreement 80 million people in the United States will now have access to its prostate cancer test. (Reporting by Robert-Jan Bartunek) Full Story	Top
Amgen, Cytokinetics heart failure drug misses goal in study  Monday, Sep 02, 2013 11:01 PM PDT By Ben Hirschler AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Despite the setback in the 613-patient trial using an intravenous formulation of the medicine omecamtiv mecarbil in hospitals, Amgen said it would continue testing an oral version of the drug in a separate Phase II study. The combined results from the tests will determine whether the medicine advances into final Phase III testing or is discontinued. ... Full Story	Top
Novartis says EU approves Ilaris to treat childhood arthritis  Monday, Sep 02, 2013 10:34 PM PDT ZURICH (Reuters) - Novartis said on Tuesday its arthritis drug Ilaris was approved in the European Union to treat children aged two years and older. Novartis said Ilaris is already sold for treating cryopyrin-associated periodic syndromes, a rare inflammatory disorder. Tuesday's approval is for active systemic juvenile idiopathic arthritis (SJIA), a debilitating disease that can affect a child's growth. The United States approved Ilaris for children in May. (Reporting By Katharina Bart) Full Story	Top
Facebook peer groups may be useful for HIV education  Monday, Sep 02, 2013 02:04 PM PDT By Andrew M. Seaman NEW YORK (Reuters Health) - Groups on the popular networking site Facebook may help educate men about HIV prevention and testing, a new study suggests. Researchers found that specially-created Facebook social media groups helped encourage men who have sex with men to reach out for information about testing themselves at home for HIV. ... Full Story	Top
Italian poultry worker tests positive for avian flu  Monday, Sep 02, 2013 10:29 AM PDT ROME (Reuters) - A man who works with poultry in Italy has tested positive for avian influenza following outbreaks among birds on farms in the northern Emilia Romagna region, the Italian Health Ministry said on Monday. Italian authorities have been culling thousands of birds since the discovery of the H7N7 strain on several farms in August, the first outbreaks of highly pathogenic avian influenza (HPAI) in Italian poultry since 2000. The Ministry said the affected man, who was exposed to sick poultry during work in contaminated areas, has contracted conjunctivitis as a result of his infection. ... Full Story	Top
British cost watchdog recommends Thrombogenics eye drug  Monday, Sep 02, 2013 09:00 AM PDT BRUSSELS (Reuters) - Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE. Jetrea, which treats vitreomacular adhesion, an ageing-related vision problem that can lead to blindness, was recommended for full reimbursement, also for those patients with early stage symptoms, Thrombogenics said. (Reporting by Robert-Jan Bartunek) Full Story	Top
Hospital to home focus may reduce readmissions: study  Monday, Sep 02, 2013 06:32 AM PDT By Andrew M. Seaman NEW YORK (Reuters Health) - Helping people who were recently released from a hospital understand how to care for themselves and informing their primary care doctors about their stay may reduce their risk of being admitted back into the hospital, says a new study. Researchers found that implementing a statewide transitional care program for North Carolinians on Medicaid - the state and federal insurance for the poor - was linked to a 20 percent reduction in patients' risk of going back to the hospital during the next year. ... Full Story	Top
Novartis heart failure drug effective across patient groups  Monday, Sep 02, 2013 05:00 AM PDT By Ben Hirschler AMSTERDAM (Reuters) - An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed. The drug, serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is viewed as an important medicine in the Swiss drugmaker's developmental pipeline. Analysts at Jefferies expect the drug to generate peak sales of $1.5 billion a year. ... Full Story	Top
HEMP Party has high ambitions in Australian election  Monday, Sep 02, 2013 03:18 AM PDT SYDNEY (Reuters) - Australia's HEMP Party formally launched its election campaign on Monday with a call for cannabis to be legalized for personal and medical use, just as it is now for industrial purposes. Members of HEMP - Help End Marijuana Prohibition - inflated a 10-meter (33-foot) plastic replica of a joint outside the state police commissioner's office in Sydney and said Australia's jails were overflowing with people criminalized for no good reason. "America has given us huge encouragement," said HEMP president Michael Balderstone. ... Full Story	Top
Doctors get good and bad safety news on diabetes drugs  Monday, Sep 02, 2013 02:53 AM PDT By Ben Hirschler AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately. Reassuringly, the medicines were not associated with increased rates of either inflammation of the pancreas or cancer - something that has been a worry in the past. However, in the case of AstraZeneca and Bristol-Myers Squibb's approved drug Onglyza, there was a small increase in hospitalizations for heart failure. ... Full Story	Top
Not your grandmother's gym class  Monday, Sep 02, 2013 01:15 AM PDT By Dorene Internicola NEW YORK (Reuters) - Physical education in the United States has come a long way since the one-size-fits-all regimen of jumping jacks and rope climbing that was the bane of the baby boomer generation. Today, where children learn can determine the type of fitness lessons they receive. ... Full Story	Top

You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.